San Diego-primarily based Viking Therapeutics marked alone as a significant competitor inside the weight loss drug marketplace in February immediately after revealing promising information from the mid-phase trial of experimental drug VK2735, which recommended it rivaled—and outperformed—Novo and Lilly drugs when provided to be a weekly injecti